Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.53 |
| ▸ | CDC25B | P30305 | 4/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.53 |
| ▸ | CDC25A | P30304 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12018371 | 1.00 | PPARA (0.55) | PPARAPTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL400187 | 1.00 | PPARA (0.55) | PPARAPTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL1414710 | 1.00 | PPARA (0.55) | PPARAPTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL2212074 | 1.00 | PPARA (0.55) | PPARAPTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL1414711 | 1.00 | PPARA (0.55) | PPARAPTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL12055688 | 1.00 | PPARA (0.55) | PPARAPTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL3449019 | 1.00 | PPARA (0.55) | PPARAPTPN1CDC25BPTPN2CDC25A | |
| Hydrochloric Acid SCHEMBL28347451 | 0.99 | PPARA (0.54) | PPARAPTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL24814238 | 0.90 | KLK5 (0.54) | PPARAPTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL9545038 | 0.90 | KLK5 (0.54) | PPARAPTPN1CDC25BPTPN2CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12625431-B2 | EUV resist underlayer film-forming composition | NISSAN CHEMICAL CORPORATION (JP) | 2026-05-12 | — | — | US | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-12358951-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2025-03-06 | — | — | US | disclosed |
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4433453-A1 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | Icagen, LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (MA) | 2024-08-06 | — | — | US | disclosed |
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2023091554-A9 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | ICAGEN, LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-0296574-A2 | Cholecystokinin analogs for controlling appetite | F. HOFFMANN-LA ROCHE AG (CH) | 1988-12-28 | — | — | EP | disclosed |
| EP-0285061-A2 | Cyclic peptides and their preparation | F. HOFFMANN-LA ROCHE AG (CH) | 1988-10-05 | — | — | EP | disclosed |
| EP-0277419-A2 | Therapeutic somatostatin analogues | THE ADMINISTRATORS OF THE TULANE UNIVERSITY EDUCATIONAL FUND (US) | 1988-08-10 | — | — | EP | disclosed |
| US-4734400-A | BRONCHODILATION WITHOUT CARDIOVASCULAR SIDE EFFECTS | HOFFMANN-LA ROCHE INC. (US) | 1988-03-29 | — | — | US | disclosed |
| EP-0099286-B1 | COMPOUND CONTAINING A TRIPEPTIDE SEQUENCE OF THE THREONYL-LYSYL PROLINE-TYPE, OR SIMILAR, USEFUL AS AN ANTI-INFLAMMATORY, ANTI-ALLERGIC OR ANTALGESIC AGENT | INSTITUT PASTEUR DE LILLE (FR) | 1987-05-20 | — | — | EP | disclosed |
| EP-0214872-A2 | Somatostatin analoge | The Administrators of The Tulane Educational Fund (US) | 1987-03-18 | — | — | EP | disclosed |
| US-4605641-A | BRONCHODILATOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1986-08-12 | — | — | US | disclosed |
| EP-0099286-A1 | Compound containing a tripeptide sequence of the threonyl-lysyl proline-type, or similar, useful as an anti-inflammatory, anti-allergic or antalgesic agent | INSTITUT PASTEUR DE LILLE (FR) | 1984-01-25 | — | — | EP | disclosed |
| US-4146614-A | TREATMENT OF SCHIZOPHRENIA | STATE OF MICHIGAN (US) | 1979-03-27 | — | — | US | disclosed |
| US-4127525-A | ANALGESIC | VETERANS ADMINISTRATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY | 1978-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | PPARA 2191/4885PTPN1 2372/4885CDC25B 19/4885 |
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A43, F12 | PPARA 4477/4885PTPN1 1905/4885CDC25B 2498/4885 |
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | PPARA 3679/4885PTPN1 2442/4885CDC25B 47/4885 |
| US-12358951-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | PPARA 455/4885PTPN1 652/4885CDC25B 2279/4885 |
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK2AP2 | PPARA 3115/4885PTPN1 2211/4885CDC25B 50/4885 |
| US-12625431-B2 | EUV resist underlayer film-forming composition | EEF1A1, ARF1, EMG1 | PPARA 4500/4885PTPN1 912/4885CDC25B 2768/4885 |
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK1 | PPARA 3800/4885PTPN1 1669/4885CDC25B 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.